Seizure Control: Hemp Extracts & CBD Offer Benefits
7:42 p.m., kitchen lights low, a timer hums on the stove. You steady a notebook and write down: “bedtime routine, quiet music, new wellness plan.” This piece explains—in plain English—how families explore hemp-derived CBD in the broader seizure conversation, what high-quality evidence does and doesn’t show, and how to proceed safely with your clinician.
Table of Contents
Understanding How CBD Saved My Child’s Seizures Basics
Families often hear anecdotal stories about seizure improvement with CBD. It’s important to separate story from evidence, and to keep expectations measured. Cannabidiol (CBD) is a non-intoxicating compound found in hemp and cannabis. A prescription, purified form of CBD (not a dietary supplement) has been studied as an add-on to standard seizure medications in specific pediatric epilepsies; results vary by person and diagnosis.
- Start with quality research: use randomized, peer-reviewed sources when possible (see citations below).
- Look for third-party testing: wherever you shop, use batch-matched Certificates of Analysis (COAs).
Bottom line: Clear definitions and credible sources help you and your clinician make safer choices.
A Day-In-The-Life Story
The bedtime lamps are warm; the white-noise machine purrs. You mark the notebook: “new oil, same evening routine.” The goal isn’t instant transformation—it’s to notice small signals over weeks: fewer startle moments, steadier mornings, better notes to share at the next appointment.
What the Research Shows
High-quality trials have evaluated purified, prescription CBD as adjunct therapy for certain severe childhood epilepsies. Findings are encouraging but not universal, and safety monitoring is required.
- Dravet syndrome: A randomized, double-blind, placebo-controlled trial reported reduced convulsive-seizure frequency with adjunct CBD versus placebo over 14 weeks. Individual responses varied.
- Lennox–Gastaut syndrome: Phase 3 trials reported reductions in drop-seizure frequency with adjunct CBD compared to placebo.
- Safety signals to watch: dose-related liver enzyme elevations (especially with valproate) and sedation/somnolence; clinicians often monitor LFTs and review concomitant meds (e.g., clobazam).
- Expect variability: Benefits, side effects, and time-to-effect differ; track observations and review with your clinician.
Bottom line: Evidence supports adjunct use in specific syndromes under medical supervision; supplements are not the same as prescription products studied in trials.
How to Get Started Safely
- Start low; change one variable at a time. Give a consistent window to observe before adjusting.
- Use batch-matched COAs. Confirm potency and contaminant screening for the exact lot you have.
- Medication review first. CBD can interact with liver-metabolized medicines; discuss clobazam, valproate, and others with your clinician.
- Health considerations. If pregnant/breastfeeding, with liver disease, or managing complex conditions, talk to a clinician before use.
- Track consistently. See the template below; bring notes to appointments.
Formats: Oils vs Gummies vs Topicals vs Flower
- Oils/Tinctures: Flexible serving control; relatively faster onset than edibles; neutral to herbal flavor depending on carrier and terpenes.
- Edibles (gummies/capsules): Slower onset, longer duration; fixed piece size can help consistency.
- Topicals: Local use; not intended for systemic seizure management.
- Flower/Inhalables: Fast onset but not suitable for many families; additional considerations apply.
COA Checklist
- Batch/lot number on bottle matches the COA PDF
- Potency listed per mL/per piece
- Contaminants: pesticides, heavy metals, residual solvents = “Pass/ND”
- Recent test date from an accredited, third-party lab
Tracking Template
Date / Time: Format & Serving (plain description; no dosages): Context (sleep, meals, stressors): T+60 / T+120 observations: Evening / Sleep notes: Next-day energy/mood (1–5): Notes to discuss with clinician:
Choosing Quality Products
Look for brands that publish batch-matched COAs, avoid contaminant flags, and offer transparent labeling (terpenes, carrier oil, lot number). Never treat or replace prescribed therapy based on an over-the-counter product without medical guidance.
- Third-party lab testing
- Clear labeling
- Reputable companies
Bottom line: Quality, transparency, and clinician oversight matter.
Frequently Asked Questions
Is How CBD Saved My Child’s Seizures right for me?
This depends on your individual health needs. Consult with a healthcare provider for personalized advice.
How do I know if a product is high quality?
Look for third-party lab testing, clear labeling, and companies with good reputations in the industry.
Further reading
References
- Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. NEJM. 2017. (Randomized, double-blind trial).
- Thiele EA, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. NEJM. 2018. (Randomized, double-blind trial).
- FDA Prescribing Information: Epidiolex (cannabidiol) oral solution—Warnings/Precautions (liver enzymes, interactions).
- Post-hoc time-to-onset analyses from LGS phase 3 programs (GWPCARE3/4).
- Stanford medicine cannabis research
- University of Pennsylvania studies
- MIT cannabis technology
- UCLA medical research
- American Medical Association position
- American Pharmacists Association
- International Association Pain
- World Health Organization expert committee
- American Academy Neurology
- Consortium for Medicinal Cannabis
Seizure Control: Hemp Extracts & CBD Offer Benefits
7:42 p.m., kitchen lights low, a timer hums on the stove. You steady a notebook and write down: “bedtime routine, quiet music, new wellness plan.” This piece explains—in plain English—how families explore hemp-derived CBD in the broader seizure conversation, what high-quality evidence does and doesn’t show, and how to proceed safely with your clinician.
Table of Contents
Understanding How CBD Saved My Child’s Seizures Basics
Families often hear anecdotal stories about seizure improvement with CBD. It’s important to separate story from evidence, and to keep expectations measured. Cannabidiol (CBD) is a non-intoxicating compound found in hemp and cannabis. A prescription, purified form of CBD (not a dietary supplement) has been studied as an add-on to standard seizure medications in specific pediatric epilepsies; results vary by person and diagnosis.
- Start with quality research: use randomized, peer-reviewed sources when possible (see citations below).
- Look for third-party testing: wherever you shop, use batch-matched Certificates of Analysis (COAs).
Bottom line: Clear definitions and credible sources help you and your clinician make safer choices.
A Day-In-The-Life Story
The bedtime lamps are warm; the white-noise machine purrs. You mark the notebook: “new oil, same evening routine.” The goal isn’t instant transformation—it’s to notice small signals over weeks: fewer startle moments, steadier mornings, better notes to share at the next appointment.
What the Research Shows
High-quality trials have evaluated purified, prescription CBD as adjunct therapy for certain severe childhood epilepsies. Findings are encouraging but not universal, and safety monitoring is required.
- Dravet syndrome: A randomized, double-blind, placebo-controlled trial reported reduced convulsive-seizure frequency with adjunct CBD versus placebo over 14 weeks. Individual responses varied.
- Lennox–Gastaut syndrome: Phase 3 trials reported reductions in drop-seizure frequency with adjunct CBD compared to placebo.
- Safety signals to watch: dose-related liver enzyme elevations (especially with valproate) and sedation/somnolence; clinicians often monitor LFTs and review concomitant meds (e.g., clobazam).
- Expect variability: Benefits, side effects, and time-to-effect differ; track observations and review with your clinician.
Bottom line: Evidence supports adjunct use in specific syndromes under medical supervision; supplements are not the same as prescription products studied in trials.
How to Get Started Safely
- Start low; change one variable at a time. Give a consistent window to observe before adjusting.
- Use batch-matched COAs. Confirm potency and contaminant screening for the exact lot you have.
- Medication review first. CBD can interact with liver-metabolized medicines; discuss clobazam, valproate, and others with your clinician.
- Health considerations. If pregnant/breastfeeding, with liver disease, or managing complex conditions, talk to a clinician before use.
- Track consistently. See the template below; bring notes to appointments.
Formats: Oils vs Gummies vs Topicals vs Flower
- Oils/Tinctures: Flexible serving control; relatively faster onset than edibles; neutral to herbal flavor depending on carrier and terpenes.
- Edibles (gummies/capsules): Slower onset, longer duration; fixed piece size can help consistency.
- Topicals: Local use; not intended for systemic seizure management.
- Flower/Inhalables: Fast onset but not suitable for many families; additional considerations apply.
COA Checklist
- Batch/lot number on bottle matches the COA PDF
- Potency listed per mL/per piece
- Contaminants: pesticides, heavy metals, residual solvents = “Pass/ND”
- Recent test date from an accredited, third-party lab
Tracking Template
Date / Time: Format & Serving (plain description; no dosages): Context (sleep, meals, stressors): T+60 / T+120 observations: Evening / Sleep notes: Next-day energy/mood (1–5): Notes to discuss with clinician:
Choosing Quality Products
Look for brands that publish batch-matched COAs, avoid contaminant flags, and offer transparent labeling (terpenes, carrier oil, lot number). Never treat or replace prescribed therapy based on an over-the-counter product without medical guidance.
- Third-party lab testing
- Clear labeling
- Reputable companies
Bottom line: Quality, transparency, and clinician oversight matter.
For readers exploring a full-spectrum evening option, Original 850 Tincture offers a hemp extract with batch-matched COAs and straightforward labeling—useful when you’re keeping a detailed wellness log.
Frequently Asked Questions
Is How CBD Saved My Child’s Seizures right for me?
This depends on your individual health needs. Consult with a healthcare provider for personalized advice.
How do I know if a product is high quality?
Look for third-party lab testing, clear labeling, and companies with good reputations in the industry.
Further reading
References
- Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. NEJM. 2017. (Randomized, double-blind trial).
- Thiele EA, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. NEJM. 2018. (Randomized, double-blind trial).
- FDA Prescribing Information: Epidiolex (cannabidiol) oral solution—Warnings/Precautions (liver enzymes, interactions).
- Post-hoc time-to-onset analyses from LGS phase 3 programs (GWPCARE3/4).
- Stanford medicine cannabis research
- University of Pennsylvania studies
- MIT cannabis technology
- UCLA medical research
- American Medical Association position
- American Pharmacists Association
- International Association Pain
- World Health Organization expert committee
- American Academy Neurology
- Consortium for Medicinal Cannabis
Leave a Reply